From the Journals

One-third of sunscreens fall short of AAD recommendations


 

FROM JAAD

Sunscreens sold by two major retailers in the United States in 2017 are more adherent to the American Academy of Dermatology recommendations for sun protection than in 2014, but approximately 35% still do not meet the AAD criteria, according to results of a new study.

sunscreen bottle on beach mark wragg/iStockphoto.com
Ariel E. Eber of the University of Miami department of dermatology and cutaneous surgery and associates conducted the follow-up study to determine whether more products met the AAD criteria in 2017. They reviewed products listed on the websites of Walmart (251 products) and Walgreens (221 products) on Jan. 25, 2017.

Overall, about 65% of Walmart products and 73% of Walgreens products met all three recommendations, a significant increase from 2014 (P less than .01). When the products were broken down by recommendation, more than 90% in 2017 offered broad-spectrum coverage, and more than 75% offered 40-80 minutes of water resistance, representing significant increases from 2014(J Am Acad Dermatol. 2017 Aug;77[2]:377-9).

The proportion of products with SPF 30 or higher “remained stable, possibly because there were already many to begin with,” noted the authors, who found that 82% of the Walmart products and 86% of the Walgreens products had an SPF of at least 30.

Of the 31 products with tanning and bronzing on their primary display, however, only 6 met the three AAD criteria for sun protection; these findings were similar to the findings in 2014.

“Our study demonstrates that sunscreens available at major retailers more closely adhere to AAD guidelines in 2017 than in 2014, but there remains room for improvement,” they said, pointing out that almost 35% of products sold at Walmart, the largest U.S. retailer, did not meet all three recommendations and that “tanning and bronzing products continue to fail to meet AAD criteria.”

The researchers had no financial conflicts to disclose.

Recommended Reading

CC-220 shows efficacy, safety concerns in phase II SLE trial
MDedge Dermatology
Canagliflozin gets boxed warning for amputation
MDedge Dermatology
Screen for comorbidities in pyoderma gangrenosum
MDedge Dermatology
Topical JAK inhibitor showed promise in facial vitiligo
MDedge Dermatology
FDA approves first specific treatment for giant cell arteritis
MDedge Dermatology
Treatment challenges for lichen planopilaris
MDedge Dermatology
My face is all red!
MDedge Dermatology
Study confirms new mutation, possible therapeutic target in epidermolysis bullosa
MDedge Dermatology
Isotretinoin patients need not postpone skin surgery
MDedge Dermatology
Subsequent squamous cell carcinoma risk higher in HIV patients with low CD4 count
MDedge Dermatology

Related Articles